ClinicalTrials.gg
CompletedNCT00296803Updated Jan 11, 2011

PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome

A Phase 4 interventional study of clopidogrel in Metabolic Syndrome x, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-01-11.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 579 studies in Metabolic Syndrome with a site in United States — 62 open to participants now, 84 under way, 3 of them phase 3. Metabolic Syndrome · United States.

Enrollment
57th of 491
216 · median 48
Started
2005
with 25 others
Phase 4
44 of 579
5 open now
Registered
49th of 579
by date

Among the 579 studies in Metabolic Syndrome with a site in United States, this one is the 57th largest by enrollment of the 491 interventional ones that give a count, is one of 26 that started in 2005, is one of 44 in phase 4, and was the 49th registered.

Metabolic Syndrome

2,117 studies on the registry are indexed under Metabolic Syndrome; 347 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

62 of the 579 studies in Metabolic Syndrome with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 232 Metabolic Syndrome studies recruiting now, 68 (29%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 579 studies in Metabolic Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to examine the effects of clopidogrel compared to placebo on markers of inflammation in subjects with metabolic syndrome who are receiving background therapy including low dose aspirin.

03

Conditions studied

  • Metabolic Syndrome x

Browse trials for

Keywords

  • metabolic syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women at least 18 years old
  2. Women must be for one year, surgically sterilized, or using a medically accepted method of and must agree to use an effective method of contraception throughout the study.
  3. Subject must meet 3 of the 5 National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATP III) criteria for the classification of metabolic syndrome: triglycerides >/= 150 mg/dL; blood pressure (BP): systolic blood pressure (SBP) >/= 130 mmHg/diastolic blood pressure (DBP) > 85 mmHg; fasting glucose >/= 110 mg/dL; waist circumference: men - > 101.6 cm (40 in)/women - > 88.9 cm (35 in); high-density lipoprotein (HDL) cholesterol: men - \< 40 mg/dL/women - \< 50 mg/dL.
  4. Subject has high-sensitivity C-reactive protein (hs-CRP) levels of >/= 2.0 but \<10.0 mg/L at the Screening Visit (Week -2).
  5. Current medication regimen must be stable for six (6) weeks, i.e. no initiation of new prescription medication nor change in dosage of any previously initiated medication within three months of entering this study.
  6. Subject is normally active and judged to be in good health, based on medical history, routine safety laboratory tests (Screening Visit, Week -2), and a brief physical examination (Week -2).

Exclusion criteria

Exclusion Criteria:

  1. Intolerance or to the use of clopidogrel or aspirin.
  2. Thrombocytopenia as defined by count \< 100,000/mm3.
  3. Current use or use within the past 3 months of oral anticoagulants, or dipyridamole or thienopyridine (ticlopidine or open-label clopidogrel) or oral .
  4. Daily aspirin in excess of 81 mg, or chronic use of non-steroidal anti-inflammatory agents.
  5. Use of oral hormone replacement therapy or oral including transdermal patch.
  6. History of pathologic bleeding (i.e., peptic ulcer or intracranial hemorrhage).
  7. History of chronic inflammatory disease or any recent medical event(s) resulting in tissue injury, infection, or inflammation.
  8. Myocardial infarction, coronary artery bypass graft, or angioplasty within the 6 months prior to Screening.
  9. Uncontrolled hypertension (systolic blood pressure >/= 180 mmHg or diastolic blood pressure >/= 100 mmHg) at Screening.
  10. History or presence of cancer in the past 2 years, except for successfully resected basal cell carcinoma of the skin.
  11. Recent history (within the past 12 months) for alcohol or substance abuse.
  12. Currently taking another study medication or has taken investigational study medication within 30 days prior to Screening Visit.
  13. Any condition the Investigator believes would interfere with evaluation of the subject, or which could put the subject at undue risk.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
216 participants

Interventions

06

What researchers measure

Primary outcomes

  1. To assess the effects of clopidogrel + aspirin vs placebo + aspirin on hs-CRP, CD40-ligand, soluble P-selectin, and other selected biomarkers in subjects with metabolic syndrome and elevated hs-CRP levels at study baseline

07

Study locations

1 site
  • Sanofi-Aventis
    Bridgewater, New Jersey 08807, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2006
First posted
Feb 27, 2006
Start
Nov 2005
CompletionActual
Aug 2006
Last update
Jan 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00296803
Lead sponsor
Sanofi
First posted
Feb 27, 2006
Start date
Nov 2005
Completion
Aug 2006
Last update
Jan 11, 2011

Study contacts

Lisa Lilienthal, M.S.
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion